Prolongation of the corrected QT interval can lead to the deadly arrhythmia torsades de pointes. There are many risk factors for corrected QT prolongation, one being medication. The goal of this case report is to add to the limited literature surrounding the possibility of torsades de pointes when levofloxacin and fluconazole are used concomitantly. Additionally, provide guidance for patient factors that need to be assessed when prescribing the two drugs.
Woosley RL, Heise CW and Romero KA. QTdrugs list, www.crediblemeds.org (2018, accessed 16 November 2018).
2.
RodenDM. Predicting drug-induced QT prolongation and torsades de pointes. J Physiol2016; 594: 2459–2468.
3.
YapYGCammAJ. Drug induced QT prolongation and torsades de pointes. Heart2003; 89: 1363–1372.
4.
Al-KhatibSMStevensonWGAckermanMJ, et al.2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol2018; 72. : e91–220; DOI: 10.1016/j.jacc.2017.10.054.
5.
AbrahamJMSalibaWIVeksteinC, et al.Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol2015; 8: 772–776.
6.
YarlagaddaBVuddandaVDarT, et al.Safety and efficacy of inpatient initiation of dofetilide versus sotalol for atrial fibrillation. J Atr Fibrillation2017; 10: 1805–1805.
7.
RodenDM. Drug-induced prolongation of the QT interval. N Engl J Med2004; 350: 1013–1022.
8.
ChidiacC. Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin). Med Mal Infect2015; 45: 348–373.
9.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
10.
ZeuliJDWilsonJWEstesLL. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents Chemother2013; 57: 1121–1127.
11.
DrewBJAckermanMJFunkM, et al.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol2010; 55: 934–947.
12.
GandhiPJMenezesPAVuHT, et al.Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm2003; 60: 2479–2483.
